Is Inovio Pharmaceuticals a Buy?
In 2020, coronavirus vaccine developer Inovio Pharmaceuticals (NASDAQ: INO) has enriched some biotech investors and wreaked havoc for others. It all depends on when you got in on the action.
If you invested $10,000 in the company this time last year, that principal would have grown to over $36,230. However, for those who became Inovio shareholders in mid-July as part of the coronavirus vaccine hype, an investment of $10,000 would be worth just over $4,000 in less about four months. The company has endured several dramatic swings in its stock price over the past 11 months. Can Inovio continue its momentum of wealth creation for early birds and recover losses for investors who were late to the game?
Image source: Getty Images.
Source Fool.com
